Our Dermatol Online 2014; 5(1): 18
Date of submission: 26.12.2014 / acceptance: 06.01.2014
Conflicts of interest: None
PSORIASIS UNCOVERED – COMORBID CONDITIONS WITH SPECIAL REFERENCE TO METABOLIC SYNDROME
by
Belliappa Pemmanda Raju, Umashankar Nagaraju
COMMENT:
Dr Rania Mounir Abdel Hay
Department of Dermatology, Faculty of Medicine, Cairo University, Egypt
E-mail: omleila2@yahoo.com
How to cite an article: Abdel Hay RM. Comment: Psoriasis Uncovered – Comorbid Conditions with Special Reference to Metabolic Syndrome. Our Dermatol Online. 2014;5(1): 18.
Very interesting article, we should take care that the management of psoriasis should be shifted towards comprehensive disease management.
– Obesity may increase risk of liver and renal toxicity to Methotrexate and cyclosporine,
– Obesity may decrease the short-term clinical response to all systemic treatment,
– Decreasing body weight improves the response of obese patients to low dose cyclosporine therapy,
– Drugs indicated in co morbidities may exacerbate psoriasis; e.g ACEI, anticoagulants, diuretics, B blockers, and psycholeptics.
Drugs used to treat psoriasis can aggravate metabolic syndrome and co morbidities; e.g Cyclosporine may lead to hypertension, or impairment of kidneys, also Acitretine may change glucose tolerance, induce hyperlipidaemia or hepatopathy, also methotrexate may have hepatopathic effects.
Comments are closed.